RVNC News

News
all
press releases
The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories announced last month.
Stocktwits
The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.
Stocktwits

Advertisement|Remove ads.